Entrada Therapeutics Inc [NASDAQ: TRDA] plunged by -$0.18 during the normal trading session on previous day and reaching a high of N/A during the day while it closed the day at $7.03.
Entrada Therapeutics Inc stock has also loss -11.01% of its value over the past 7 days. However, TRDA stock has declined by -34.60% in the 3 months of the year. Over the past six months meanwhile, it has lost -60.19% and lost -59.34% year-on date.
The market cap for TRDA stock reached $266.81 million, with 37.94 million shares outstanding and 22.21 million shares in the current float. Compared to the average trading volume of 141.35K shares, TRDA reached a trading volume of 118694 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Entrada Therapeutics Inc [TRDA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TRDA shares is $20.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TRDA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH MKM have made an estimate for Entrada Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 06, 2024. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on January 05, 2024, representing the official price target for Entrada Therapeutics Inc stock. Previously, the target price had yet another raise to $25, while H.C. Wainwright analysts kept a Buy rating on TRDA stock.
The Average True Range (ATR) for Entrada Therapeutics Inc is set at 0.46, with the Price to Sales ratio for TRDA stock in the period of the last 12 months amounting to 1.55. The Price to Book ratio for the last quarter was 0.64, with the Price to Cash per share for the same quarter was set at 10.08.
TRDA stock trade performance evaluation
Entrada Therapeutics Inc [TRDA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.01. With this latest performance, TRDA shares dropped by -12.23% in over the last four-week period, additionally sinking by -60.19% over the last 6 months – not to mention a drop of -55.45% in the past year of trading.
Entrada Therapeutics Inc [TRDA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Entrada Therapeutics Inc [TRDA] shares currently have an operating margin of 2.39% and a Gross Margin at 97.83%. Entrada Therapeutics Inc’s Net Margin is presently recorded at 14.39%.
Return on Equity for this stock inclined to 4.97%, with Return on Assets sitting at 4.97%.
Entrada Therapeutics Inc [TRDA]: Institutional Ownership
There are presently around $80.11%, or 91.44%% of TRDA stock, in the hands of institutional investors. The top three institutional holders of TRDA stocks are: BAKER BROS. ADVISORS LP with ownership of 4.87 million shares, which is approximately 14.2356%. MPM ASSET MANAGEMENT LLC, holding 4.43 million shares of the stock with an approximate value of $$63.07 million in TRDA stocks shares; and MPM ASSET MANAGEMENT LLC, currently with $$62.82 million in TRDA stock with ownership which is approximately 12.8973%.
